Pioneering non-coding RNA therapeutics through AI-driven design and computational biology
While traditional drug discovery targets the 2% coding genome, we focus on the vast untapped therapeutic potential of non-coding RNA
100,000+ non-coding RNA species offer unprecedented opportunities for therapeutic intervention
85% of disease-associated genetic variants occur in non-coding regions
10x faster target discovery through integrated computational biology
Targeting critical unmet medical needs with RNA-based interventions
Chronic Liver Disease
Neurodegenerative Disorder
End-to-end solution from target discovery to clinical candidate
Multi-omics data integration and AI-powered analysis identify high-confidence ncRNA targets with validated disease associations
Machine learning models optimize ASO and siRNA candidates for superior efficacy, specificity, and safety profiles
Comprehensive preclinical packages with CMC, regulatory strategy, and robust IP protection for clinical development
Peer-reviewed platforms advancing RNA research globally
Small RNA-seq Analysis
Expression Atlas
Single-Cell Analysis
Expert analysis transforming complex biological data into actionable insights
Interested in partnerships, collaborations, or joining our team? Let's talk.
Business: info@accelerna.ai | Careers: careers@accelerna.ai
Worcester, MA 01604, USA | +1-617-229-9738